» Articles » PMID: 18381413

Pancreatic Stellate Cells: Partners in Crime with Pancreatic Cancer Cells

Overview
Journal Cancer Res
Specialty Oncology
Date 2008 Apr 3
PMID 18381413
Citations 243
Authors
Affiliations
Soon will be listed here.
Abstract

Pancreatic stellate cells (PSC) produce the stromal reaction in pancreatic cancer, but their role in cancer progression is not fully elucidated. We examined the influence of PSCs on pancreatic cancer growth using (a) an orthotopic model of pancreatic cancer and (b) cultured human PSCs (hPSC) and human pancreatic cancer cell lines MiaPaCa-2 and Panc-1. Athymic mice received an intrapancreatic injection of saline, hPSCs, MiaPaCa-2 cells, or hPSCs + MiaPaCa-2. After 7 weeks, tumor size, metastases, and tumor histology were assessed. In vitro studies assessed the effect of cancer cell secretions on PSC migration and the effect of hPSC secretions on cancer cell proliferation, apoptosis, and migration. Possible mediators of the effects of hPSC secretions on cancer cell proliferation were examined using neutralizing antibodies. Compared with mice receiving MiaPaCa-2 cells alone, mice injected with hPSCs + MiaPaCa-2 exhibited (a) increased tumor size and regional and distant metastasis, (b) fibrotic bands (desmoplasia) containing activated PSCs within tumors, and (c) increased tumor cell numbers. In vitro studies showed that, in the presence of pancreatic cancer cells, PSC migration was significantly increased. Furthermore, hPSC secretions induced the proliferation and migration, but inhibited the apoptosis, of MiaPaCa-2 and Panc-1 cells. The proliferative effect of hPSC secretions on pancreatic cancer cells was inhibited in the presence of neutralizing antibody to platelet-derived growth factor. Our studies indicate a significant interaction between pancreatic cancer cells and stromal cells (PSCs) and imply that pancreatic cancer cells recruit stromal cells to establish an environment that promotes cancer progression.

Citing Articles

MYH knockdown in pancreatic cancer cells creates an exploitable DNA repair vulnerability.

Ephraums J, Youkhana J, Raina A, Schulstad G, Croft K, Mawson A Neoplasia. 2025; 61:101138.

PMID: 39938155 PMC: 11869960. DOI: 10.1016/j.neo.2025.101138.


Spatial profiling of endoplasmic reticulum stress markers in tumor associated cells predicts patient outcomes in pancreatic cancer.

Porter G, Norris M, Apte M, Merlot A Neoplasia. 2025; 60:101115.

PMID: 39818177 PMC: 11786694. DOI: 10.1016/j.neo.2024.101115.


The multi-faceted roles of cancer-associated fibroblasts in pancreatic cancer.

Kwon J, Vera R, Fernandez-Zapico M Cell Signal. 2025; 127:111584.

PMID: 39756502 PMC: 11807759. DOI: 10.1016/j.cellsig.2024.111584.


Dual rectification of metabolism abnormality in pancreatic cancer by a programmed nanomedicine.

Wu B, Wang Z, Liu J, Li N, Wang X, Bai H Nat Commun. 2024; 15(1):10526.

PMID: 39627234 PMC: 11615375. DOI: 10.1038/s41467-024-54963-y.


Updates in Immunotherapy for Pancreatic Cancer.

Chick R, Pawlik T J Clin Med. 2024; 13(21).

PMID: 39518557 PMC: 11546190. DOI: 10.3390/jcm13216419.